Acute respiratory distress, digestive hemorrhage, and severe mucocutaneous toxicity have been reported as OTOT effects in several clinical trials, particularly with Her2 (84)-, CLDN18.2 (85)- and EGFR (41, 42)-targeted CAR-T cells. Here, ERBB2 is linked to Respiratory distress.